Data Insights

By Company Name

By Disease Name

By Drug Name

By Themes

Showing 5 results out of 5

Data Insights

Dinutuximab beta by Recordati for Neuroblastoma: Likelihood of Approval

Dinutuximab beta is under clinical development by Recordati and currently in Phase II for Neuroblastoma. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Dinutuximab Beta in Neuroblastoma

Data Insights

Siltuximab by Recordati for Pain: Likelihood of Approval

Siltuximab is under clinical development by Recordati and currently in Phase II for Pain. According to GlobalData, Phase II drugs...

Likelihood of Approval and Phase Transition Success Rate Model - Siltuximab in Pain

Data Insights

Pasireotide by Recordati for Hypoglycemia: Likelihood of Approval

Pasireotide is under clinical development by Recordati and currently in Phase II for Hypoglycemia. According to GlobalData, Phase II drugs...

Likelihood of Approval and Phase Transition Success Rate Model - Pasireotide in Hypoglycemia

Data Insights

Pasireotide LA by Recordati for Hyperprolactinaemia: Likelihood of Approval

Pasireotide LA is under clinical development by Recordati and currently in Phase II for Hyperprolactinaemia. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Pasireotide LA in Hyperprolactinaemia

Data Insights

Pasireotide by Recordati for Hypoglycemia: Likelihood of Approval

Pasireotide is under clinical development by Recordati and currently in Phase I for Hypoglycemia. According to GlobalData, Phase I drugs...

Likelihood of Approval and Phase Transition Success Rate Model - Pasireotide in Hypoglycemia